Justin Crop, DO
Family Medicine · American Fork, UTNPI 1801090659
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 36.7% of the total.
Across 204 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$286
- Lilly USA, LLC$217
- Boehringer Ingelheim$190
- Pfizer$178
- AstraZeneca$142
- plus $1K from 29 others
Across 2 payments — averaging $40,312 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$81K
What the payments were for
- Food & beverage$3,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,183 |
| Amgen | 19 | $286 |
| Lilly USA, LLC | 14 | $217 |
| Boehringer Ingelheim | 10 | $190 |
| Pfizer | 12 | $178 |
| AstraZeneca | 10 | $142 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Tris Pharma Inc | 4 | $75 |
| GSK | 4 | $75 |
| Johnson & Johnson | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $63 |
| Novo Nordisk | 4 | $58 |
| Merck | 4 | $54 |
| Cranial Technologies, Inc | 3 | $42 |
| Eisai Inc. | 3 | $34 |
| Braintree Laboratories, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Abbott | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
| GE HealthCare | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Philips North America LLC | 1 | $13 |
| Bayer | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,222 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $63,963 |
| OzempicSemaglutide | 53 | $52,379 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $32,355 |
| JardianceEmpagliflozin | 21 | $30,568 |
| RybelsusSemaglutide | 16 | $25,091 |
| MounjaroTirzepatide | 20 | $21,861 |
| TrulicityDulaglutide | 19 | $19,649 |
| TradjentaLinagliptin | 13 | $10,060 |
| Omeprazole | 205 | $3,747 |
| Gabapentin | 127 | $3,623 |
| Lurasidone Hcl | 18 | $3,466 |
| Atorvastatin Calcium | 240 | $2,986 |
| PremarinEstrogens, Conjugated | 11 | $2,812 |
| Lacosamide | 15 | $2,653 |
| Levothyroxine Sodium | 225 | $2,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $58 | $77,47169 claims |
| PfizerEliquis, Premarin | $178 | $66,77690 claims |
| Lilly USA, LLCMounjaro, Trulicity | $217 | $41,51039 claims |
| Boehringer IngelheimJardiance, Tradjenta | $190 | $40,62834 claims |
| AbbVieSynthroid | $1,183 | $1,63721 claims |
| Braintree Laboratories, Inc.Suflave | $32 | $1,33611 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $92777 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in American Fork
- Mark HafenAmerican Fork$8K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.